AstraZeneca: BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial

Press/Media

Period26 Sep 2019

Media coverage

1

Media coverage

  • TitleAstraZeneca: BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date26/09/19
    PersonsRoxana Mehran,
View all 1
View less